Suven Pharma posts net profit of Rs 74.18 crore in Q4

Published On 2020-06-21 04:00 GMT   |   Update On 2020-06-21 04:00 GMT

New Delhi: Drug firm Suven Pharmaceuticals on Thursday reported a consolidated net profit of Rs 74.18 crore for the quarter ended March 31, 2020.The company had posted a net profit of Rs 74.82 crore in the corresponding period of the previous fiscal, Suven Pharma said in a filing to the BSE.Consolidated total income of the company stood at Rs 190.10 crore during the quarter under review. It...

Login or Register to read the full article

New Delhi: Drug firm Suven Pharmaceuticals on Thursday reported a consolidated net profit of Rs 74.18 crore for the quarter ended March 31, 2020.

The company had posted a net profit of Rs 74.82 crore in the corresponding period of the previous fiscal, Suven Pharma said in a filing to the BSE.

Consolidated total income of the company stood at Rs 190.10 crore during the quarter under review. It stood at Rs 251.33 crore in the same period a year ago, it added.

"Consequent to the demerger of contract research and manufacturing services (CRAMS) undertaking of the erstwhile Suven Life Sciences Ltd as a going concern into the company, pursuant to the scheme effective from the appointed date being October 1, 2018, the financial results for the year ended March 31, 2020, are not comparable to that extent with the previous corresponding period," Suven Pharma said.

For the fiscal year 2019-20, net profit stood at Rs 317 crore. It was at Rs 109.27 crore in 2018-19.

The company''s total income stood at Rs 851.90 crore for the fiscal year ended March 2020. It was at Rs 378.43 crore in the fiscal year 2018-19.

Shares of Suven Pharmaceuticals on Thursday closed 4.36 per cent higher at Rs 347.90 per scrip on the BSE.

Read also: Natco Pharma net profit falls 23 pc at Rs 93.2 crore in Q4


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News